Investing Profile

Niall O’Donnell

InvestorVC
Managing Director at RiverVest Venture Partners
Photo of Niall O’Donnell, Managing Director at RiverVest

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
RiverVest Managing Director
$100K - $1M
$100K
15
$184.4M
CompanyStageDateRound SizeTotal Raised
Engrail Therapeutics
Series BMar 2024$160M
$220M
Co-investors: Stacie Weninger (F-Prime Capital Partners), Peter Bisgaard (Pivotal bioVenture Partners), Jasper Bos (Forbion), Heath Lukatch (Red Tree Venture Capital)
Glycomine
Series BJun 2021$35M
$35M
Co-investors: Jim Trenkle (Sanofi Ventures), Bali Muralidhar (Abingworth)
Reneo Pharmaceuticals
Series BDec 2020$95M
Series AMay 2019$50M
$150M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Bali Muralidhar (Abingworth)
Amplyx Pharmaceuticals
Series CMay 2020$53M
Series CAug 2017$67M
Series BNov 2015$41M
$160M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Alex Kahn (Generation Ventures)
Mirum Pharmaceuticals
Series ANov 2018$120M
$120M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Patrick Heron (Frazier Healthcare Partners), Jonathan Leff (Deerfield Management)
Otonomy
Series DApr 2014$49M
Series CSep 2013$46M
Series BAug 2010$39M
Series BAug 2010$39M
$180M
Co-investors: Chau Khuong (OrbiMed), Brian Dovey (Domain Associates), John McKearn (RiverVest), Jay Lichter (Avalon Ventures), Peter Bisgaard (Pivotal bioVenture Partners), Bill Harrington (Osage University Partners), Heather Preston
Lumena Pharmaceuticals
Series BMar 2014$45M
Series AMay 2013$23M
$68M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), John McKearn (RiverVest)
Excaliard Pharmaceuticals
Series ANov 2007$16M
$16M